appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Transgene Biotek Ltd
TRABI
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Transgene Biotek is a biotechnology company which operates transgene medical centers. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics
PeersCompare with peers
Biocon Ltd
Onesource Specialty Pharma Ltd
Sai Life Sciences Ltd
Panacea Biotec Ltd
3B Blackbio DX Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Result
TRANSGENE BIOTEK LTD. - 526139 - The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company, For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-AS) As Per Companies (Indian Accounting Standards) Rules, 2015. Limited Review Report On The Unaudited Standalone And Consolidated Financial Results Of The Company, For The Quarter Ended 31.12.2024 Has Also Been Approved. | Download
TRANSGENE BIOTEK LTD. - 526139 - The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company, For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-AS) As Per Companies (Indian Accounting Standards) Rules, 2015. Limited Review Report On The Unaudited Standalone And Consolidated Financial Results Of The Company, For The Quarter Ended 31.12.2024 Has Also Been Approved. | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant